Abstract:Sporadic Alzheimer’s disease (AD) is a neurodegenerative disease characterized by neurofibrillary tangles composed of hyperphosphorylated tau proteins and amyloid‐beta (Aβ) plaques. Together, these two histopathological detriments in the brain lead to progressive cognitive decline. Glycogen synthase kinase‐3 β (GSK3β), a kinase found abundantly in the brain, has been implicated in the development of these AD pathologies. GSK3β remains constituently active until phosphorylated at its inhibitory Ser9 residue. When active, GSK3β is capable of inducing tau hyperphosphorylation and can phosphorylate amyloid‐precursor protein (APP), influencing greater levels of Aβ peptide production. Lithium (Li), a GSK3β inhibitor, has been suggested as an AD prophylaxis. However, Li has also been associated with several dose‐dependent adverse side effects. The purpose of this study was thus to examine the effects of a prophylactic low‐dose Li supplementation on brain GSK3β signaling and activity. C57BL/6J male mice were given 10mg/kg/day Li or no Li in their drinking water for 6 weeks (n=12/group) and the prefrontal cortex (PFC) and hippocampal (HIP) tissues were collected for GSK3 activity assay and western blot analyses. Li mice had increased serum Li concentrations (p<0.0001) and decreased hippocampal GSK3 activity (p=0.06) as compared to control mice. pAkt Thr308 phosphorylation, a kinase immediately upstream of GSK3β capable of inducing inhibitory pGSK3β Ser9 phosphorylation, was increased in the PFC of Li mice compared to control mice (p<0.05). However, no differences in pGSK3β Ser9 or Tyr216, an activating residue, were observed between control and Li mice in both the PFC and HIP. Changes in GSK3 activity without changes in inhibitory Ser9 phosphorylation may suggest that a longer supplementation is needed to affect significant changes in the brain. Furthermore, these results demonstrate that the phosphorylation status of GSK3β may not always be a direct translation of its activity. This highlights the importance of measuring GSK3β activity alongside of measures of upstream kinases (i.e. PI3K/Akt signaling) and downstream targets to obtain a better indication of GSK3β’s overall activity within the brain. Overall, this initial work provides evidence that Li can inhibit hippocampal GSK3 activity and alter the phosphorylation status of upstream kinases at a low‐dose. Future work will examine Li’s potential prophylactic effects in a diseased model which better mimics AD (i.e. aged and metabolically‐distressed mice). This is important to further elucidate the efficacy of low‐dose Li in the prevention of AD pathologies. Support or Funding Information This work is supported by the Alzheimer Society of Brant, Haldimand Norfolk, Hamilton Halton and NSERC.

Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation

Ganoderma Lucidum Triterpenoids (glts) Reduce Neuronal Apoptosis Via Inhibition of ROCK Signal Pathway in APP/PS1 Transgenic Alzheimer's Disease Mice

Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease

Targeting glycogen synthase kinase-3 β for Alzheimer's disease: Recent advances and future Prospects

Targeting Glycogen Synthase Kinase-3Β for Alzheimer's Disease: Recent Advances and Future Prospects

The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer’s disease in rodents

GSK3 Activity is Decreased in The Hippocampus of Male Mice Supplemented with Low‐Dose Lithium in Drinking Water

β-Amyloid impairs the regulation of N-methyl-D-aspartate receptors by glycogen synthase kinase 3

A GLP-1/GIP Dual Receptor Agonist DA4-JC Effectively Attenuates Cognitive Impairment and Pathology in the APP/PS1/Tau Model of Alzheimer's Disease

Inhibition of 2-Arachidonoylglycerol Metabolism Alleviates Neuropathology and Improves Cognitive Function in a Tau Mouse Model of Alzheimer’s Disease

Programmed Cell Death Protein 1 Blockade Reduces Glycogen Synthase Kinase 3β Activity and Tau Hyperphosphorylation in Alzheimer’s Disease Mouse Models

O3–02–01: Reversal of Synaptic Plasticity and Spatial Memory Deficits in APP/PS1 Mice by Suppressing Protein Kinase GCN2

Tetrahydroxy stilbene glycoside regulates TGF-β/fractalkine/CX3CR1 based on network pharmacology in APP/PS1 mouse model

Glycogen synthase kinase-3 regulates production of amyloid-β peptides and tau phosphorylation in diabetic rat brain.

GSK-3 in Neurodegenerative Diseases

Regulation and effects of neurotrophic factors after neural stem cell transplantation in a transgenic mouse model of Alzheimer disease.

Dysregulation of the mTOR Pathway Mediates Impairment of Synaptic Plasticity in a Mouse Model of Alzheimer's Disease

Glucose 6 phosphate dehydrogenase overexpression rescues the loss of cognition in the double transgenic APP/PS1 mouse model of Alzheimer's disease

Unlocking hope: GSK-3 inhibitors and Wnt pathway activation in Alzheimer's therapy

The role of GLP-1/GIP receptor agonists in Alzheimer's disease

Ginsenoside Rg2 alleviates neurovascular damage in 3xTg-AD mice with Alzheimer's disease through the MAPK-ERK pathway